Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: A prospective evaluation

Veronica Prati; Fiorella Ruatta; Caterina Aversa; Angela Gernone; Danilo Galizia; Alessandro Bonzano; Sofia Torino; Imperia Nuzzolese; Laura Marandino; Massimo Aglietta; Cinzia Ortega

doi:10.2217/fon-2017-0385

Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: A prospective evaluation

Veronica Prati, Fiorella Ruatta, Caterina Aversa, Angela Gernone, Danilo Galizia, Alessandro Bonzano, Sofia Torino, Imperia Nuzzolese, Laura Marandino, Massimo Aglietta, Cinzia Ortega

Istituto Oncologico Candiolo

Research output: Contribution to journal › Article › peer-review

Abstract

Aim: The aim of this study is to evaluate cardiotoxicity of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer patients (pts) with cardiovascular comorbidities or coronary artery disease (CAD) risk factors. Patients & methods: We prospectively analyzed pts receiving AA in order to evaluate correlations between cardiotoxicity onset and CAD risk factors or cardiovascular comorbidities. Results: Eighty-seven pts were enrolled, with median treatment duration of 9 months (1-44). At baseline, 84 pts (96%) had CAD risk factors. During treatment four pts (4; 6%) developed hypertension and 26 pts (30%) worsened the preexisting hypertension. Median left ventricular ejection fraction were 64 and 63% at baseline and after treatment, respectively. Conclusion: AA appears to be safe in pts with cardiovascular comorbidities or CAD risk factors.

Original language	English
Pages (from-to)	443-448
Number of pages	6
Journal	Future Oncology
Volume	14
Issue number	5
DOIs	https://doi.org/10.2217/fon-2017-0385
Publication status	Published - Feb 1 2018

Keywords

abiraterone acetate
cardiovascular risk factors
frail patients
metastatic castration-resistant prostate cancer
multidisciplinary management
prospective study
safety

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon-2017-0385

Fingerprint Dive into the research topics of 'Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: A prospective evaluation'. Together they form a unique fingerprint.

Cite this

Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients : A prospective evaluation. / Prati, Veronica; Ruatta, Fiorella; Aversa, Caterina; Gernone, Angela; Galizia, Danilo ; Bonzano, Alessandro; Torino, Sofia; Nuzzolese, Imperia; Marandino, Laura; Aglietta, Massimo; Ortega, Cinzia.

In: Future Oncology, Vol. 14, No. 5, 01.02.2018, p. 443-448.

Research output: Contribution to journal › Article › peer-review

Prati, Veronica ; Ruatta, Fiorella ; Aversa, Caterina ; Gernone, Angela ; Galizia, Danilo ; Bonzano, Alessandro ; Torino, Sofia ; Nuzzolese, Imperia ; Marandino, Laura ; Aglietta, Massimo ; Ortega, Cinzia. / Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients : A prospective evaluation. In: Future Oncology. 2018 ; Vol. 14, No. 5. pp. 443-448.

@article{062ca948914b41b9afc8e498729f7701,

title = "Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: A prospective evaluation",

abstract = "Aim: The aim of this study is to evaluate cardiotoxicity of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer patients (pts) with cardiovascular comorbidities or coronary artery disease (CAD) risk factors. Patients & methods: We prospectively analyzed pts receiving AA in order to evaluate correlations between cardiotoxicity onset and CAD risk factors or cardiovascular comorbidities. Results: Eighty-seven pts were enrolled, with median treatment duration of 9 months (1-44). At baseline, 84 pts (96%) had CAD risk factors. During treatment four pts (4; 6%) developed hypertension and 26 pts (30%) worsened the preexisting hypertension. Median left ventricular ejection fraction were 64 and 63% at baseline and after treatment, respectively. Conclusion: AA appears to be safe in pts with cardiovascular comorbidities or CAD risk factors.",

keywords = "abiraterone acetate, cardiovascular risk factors, frail patients, metastatic castration-resistant prostate cancer, multidisciplinary management, prospective study, safety",

author = "Veronica Prati and Fiorella Ruatta and Caterina Aversa and Angela Gernone and Danilo Galizia and Alessandro Bonzano and Sofia Torino and Imperia Nuzzolese and Laura Marandino and Massimo Aglietta and Cinzia Ortega",

year = "2018",

month = feb,

day = "1",

doi = "10.2217/fon-2017-0385",

language = "English",

volume = "14",

pages = "443--448",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "5",

}

TY - JOUR

T1 - Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients

T2 - A prospective evaluation

AU - Prati, Veronica

AU - Ruatta, Fiorella

AU - Aversa, Caterina

AU - Gernone, Angela

AU - Galizia, Danilo

AU - Bonzano, Alessandro

AU - Torino, Sofia

AU - Nuzzolese, Imperia

AU - Marandino, Laura

AU - Aglietta, Massimo

AU - Ortega, Cinzia

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Aim: The aim of this study is to evaluate cardiotoxicity of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer patients (pts) with cardiovascular comorbidities or coronary artery disease (CAD) risk factors. Patients & methods: We prospectively analyzed pts receiving AA in order to evaluate correlations between cardiotoxicity onset and CAD risk factors or cardiovascular comorbidities. Results: Eighty-seven pts were enrolled, with median treatment duration of 9 months (1-44). At baseline, 84 pts (96%) had CAD risk factors. During treatment four pts (4; 6%) developed hypertension and 26 pts (30%) worsened the preexisting hypertension. Median left ventricular ejection fraction were 64 and 63% at baseline and after treatment, respectively. Conclusion: AA appears to be safe in pts with cardiovascular comorbidities or CAD risk factors.

AB - Aim: The aim of this study is to evaluate cardiotoxicity of abiraterone acetate (AA) in metastatic castration-resistant prostate cancer patients (pts) with cardiovascular comorbidities or coronary artery disease (CAD) risk factors. Patients & methods: We prospectively analyzed pts receiving AA in order to evaluate correlations between cardiotoxicity onset and CAD risk factors or cardiovascular comorbidities. Results: Eighty-seven pts were enrolled, with median treatment duration of 9 months (1-44). At baseline, 84 pts (96%) had CAD risk factors. During treatment four pts (4; 6%) developed hypertension and 26 pts (30%) worsened the preexisting hypertension. Median left ventricular ejection fraction were 64 and 63% at baseline and after treatment, respectively. Conclusion: AA appears to be safe in pts with cardiovascular comorbidities or CAD risk factors.

KW - abiraterone acetate

KW - cardiovascular risk factors

KW - frail patients

KW - metastatic castration-resistant prostate cancer

KW - multidisciplinary management

KW - prospective study

KW - safety

UR - http://www.scopus.com/inward/record.url?scp=85041571120&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041571120&partnerID=8YFLogxK

U2 - 10.2217/fon-2017-0385

DO - 10.2217/fon-2017-0385

M3 - Article

C2 - 29318908

AN - SCOPUS:85041571120

VL - 14

SP - 443

EP - 448

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 5

ER -